Press Releases Rani Therapeutics Holdings, Inc.

Equities

RANI

US7530181004

Real-time Estimate Cboe BZX Other stock markets 19:56:03 10/05/2024 BST			5-day change	1st Jan Change
6.39 ^USD	-5.75%		-11.33%	+90.96%

05-07	HC Wainwright Adjusts Price Target on Rani Therapeutics Holdings to $13 From $12, Maintains Buy Rating	MT
05-06	Rani Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024	05-09	AQ
Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update	05-06	AQ
Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update	03-20	AQ
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results	03-18	AQ
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results	03-15	AQ
Rani Therapeutics : RT-111 Phase 1 Data Presentation	03-12	PU
Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111)	02-05	AQ
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Rani Therapeutics Holdings, Inc. (NASDAQ: RANI)	01-09	PR
Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist	12-14	AQ
Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update	11-08	AQ
Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill® Technology Platform; Reports Preliminary Third Quarter 2023 Financial Results	11-01	AQ
The RaniPill® Capsule, Rani Therapeutics’ Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study	25/10/23	AQ
Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study	19/10/23	AQ
Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research	12/10/23	AQ
Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)	18/09/23	AQ
Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies	07/09/23	AQ
Rani Therapeutics to Participate in September Investor Conferences	06/09/23	AQ
Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update	11/08/23	AQ
Rani Therapeutics to Participate in August Investor Conferences	04/08/23	AQ
Celltrion And Rani Therapeutics To Jointly Develop Oral Formulation Of Adalimumab Biosimilar	22/06/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Rani Therapeutics Holdings, Inc.

Equities

RANI

US7530181004

Press Releases

Filters